Fecal Transplant Therapies Recommended for Recurrent C. difficile in Some Patients
Official recommendations from the American Gastroenterological Association.
c. diff bacteria © Artur - stock.adobe.com
A Clostridioides difficile infection (C. difficile) is recognized by the Centers for Disease Control and Prevention (CDC) as an ongoing public health threat with 462,000 new cases diagnosed every year. Infections are most common in those over 65 years of age and those who spend prolonged periods in assisted living, according to the CDC. Symptoms include loose and watery stools, fever and stomach tenderness.
New research from the American Gastroenterological Association (AGA), published in Gastroenterology, greenlights fecal microbiota-based therapies for immunocompetent and mildly and moderately immunocompromised adults with recurrent C. difficile infections. This recommendation does not extend to C. difficile patients who are severely immunocompromised (unless it is as a last resort) or to patients with other inflammatory bowel diseases such as irritable bowel syndrome, ulcerative colitis, pouchitis and Crohn’s disease except in the case of clinical studies.
Guidelines were decided upon by a seven-member panel selected based on clinical expertise which gathered evidence from electronic databases such as the Cochrane Central Register of Controlled Trials.
In C. difficile patients, fecal microbiota-based therapies may be considered by a patient when C. difficile infections no longer respond to antibiotics within 2 to 5 days of treatment or after the third infection.
Alternatives to fecal transplant treatment include a vancomycin taper, tapered-pulsed fidaxomicin or bezlotoxumab.
“Fecal microbiota-based therapies are effective therapy to prevent recurrent C. difficile in select patients,” the authors write. “Fecal microbiota transplant cannot yet be recommended in other gastrointestinal conditions.”
How the Contact Center Can Be a Driver of VBC Success
December 23rd 2024Historically, healthcare organizations have considered the contact center to be a cost center, a communications platform for conveying information to patients and plan members. Today, however, AI-enabled contact centers can be drivers of value, especially in a value-based care environment.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
